Arixtra safety update
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves labeling revision for Organon/Sanofi-Synthelabo's deep vein thrombosis agent Arixtra (fondaparinux) Dec. 4, removing a caveat that improved efficacy seen versus Aventis' Lovenox (enoxaparin) may have been influenced by timing of the first dose and eliminating a statement that there was a higher bleeding rate with Arixtra. In the initial review, FDA felt that the rate of bleeding and venous thromboembolisms in clinicals might have been affected by deviance from the dosing schedule (Pharmaceutical Approvals Monthly, May 1, 2002, p. 33). Other labeling revisions include the addition of VTE relative risk reduction figures. Revised labeling could allow the companies to boost sales; Arixtra's launch has been slower than expecte
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.